Navigation Links
Zosano Pharma, Inc. Appoints Nandan Oza as Chief Operations Officer

FREMONT, Calif., May 14, 2013 /PRNewswire/ -- Zosano Pharma, Inc., a privately held pharmaceutical company developing products based on its novel transdermal delivery technology, announced today a key addition to its executive team with the appointment of Nandan Oza as the company's Chief Operations Officer. In this position, Mr. Oza will guide the company's efforts in manufacturing, quality and engineering – vital activities to enable the company to accelerate the development of its innovative multi-product portfolio.

"I am pleased to welcome Nandan as our COO," said Vikram Lamba, Chief Executive Officer, Zosano Pharma. "His operational and manufacturing experience and expertise – as well as his leadership experience – will be critical in preparing Zosano for our next stage of commercial-scale manufacturing as we drive our clinical programs towards the marketplace."

Prior to joining Zosano Pharma, Mr. Oza served as Vice President, Chemistry, Manufacturing and Controls at Talon Therapeutics. He previously held the position of Vice President, Manufacturing and Supply Chain Operations at Jazz Pharmaceuticals and at Connetics Corporation (now a part of GSK). Mr. Oza also held positions of increasing responsibility at ALZA Pharmaceuticals (now part of Johnson and Johnson) in Product Development, Quality and Technical and Manufacturing Operations, progressing to his role as Executive Director, Bay Area Operations. Mr. Oza earned a Bachelor's degree (with honors) in Mechanical Engineering from the University of Houston, pursued graduate studies in Engineering from the University of California, Davis and earned an MBA from National University, San Diego, CA.

"This is an exciting time to join the Zosano Pharma team," said Mr. Oza. "The company is well positioned to move forward in commercial scale manufacturing with its ZP Patch Technology and advancing development-stage product pipeline."

About Zosano Pharma
Zosano Pharma, Inc. is a private biopharmaceutical company and a pioneer in the field of drug delivery systems. Zosano is developing products using ZP Patch Technology, a novel transdermal delivery technology based on microprojections that provide rapid and efficient systemic delivery in a convenient, needle–free, and pain–free system. Zosano is a fully integrated development company with a recently launched cGMP manufacturing capability. The company is developing products with significant commercial potential both independently and in collaboration with strategic partners. Learn more at

SOURCE Zosano Pharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Zosano Pharma, Inc. Expands Board of Directors with Addition of Kleanthis G. Xanthopoulos, Ph.D.
2. Zosano Pharma, Inc. Announces Key Strategic Hire
3. DFH Pharma, USA Partners with Hetero Group, INDIA to Develop 2nd Generation HIV Maturation Inhibitor Drugs
4. Morning Research on Sequenom, Peregrine Pharma, Onyx Pharma, and Inovio Pharma
5. Todays Research on PDL BioPharma, Dendreon, Medivation, ACADIA Pharma, and Cell Therapeutics
6. Robbins Arroyo LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against Hemispherx Biopharma, Inc.
7. InnoPharma, Inc., Announces U.S. FDA Approval of Acetylcysteine Solution, USP, 20% for Inhalation or Oral Administration
8. Galena Biopharma, Inc. Investor Presentation Now Available for On-demand Viewing at
9. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
10. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
11. Optimer Pharmaceuticals Appoints Eric Sirota as Chief Operating Officer
Post Your Comments:
(Date:6/23/2016)... ITASCA, Ill. , June 23, 2016  In a startling ... states are failing their residents by lacking a comprehensive, proven plan ... , a definitive ranking of how states are tackling the ... rating to only four states – Kentucky , ... and Vermont . Of the 28 failing states, ...
(Date:6/23/2016)... , June 23, 2016 Research and ... Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data derived ... Assessment of major trends with potential impact on the market ... of market segmentation which comprises of sub markets, regional and ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... of its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. ... James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/25/2016)... ... 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s ... setting the bar too high can result in disappointment, perhaps even self-loathing. However, those ... goal. , Research from reveals that behind the tendency to ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Those who ... with these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, ... Marne, Michigan, has released tools for healthy coping following a traumatic event. , Trauma ...
(Date:6/24/2016)... ... 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out of ... verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... throw rocks at my other children and say he was going to kill them. ...
Breaking Medicine News(10 mins):